Elios Therapeutics Presents New Phase IIb Data for Personalized Cancer Vaccine in High-Risk Melanoma Patients at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
- Friday, February 7, 2020, 7:04
- Finance
- Add a comment
AUSTIN, Texas, Feb. 7, 2020 /PRNewswire/ — Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced that the Company presented a subgroup analysis of the prospective, randomized, double-blind, placebo-controlled Phase…
About the Author
adminasapcorp has written 39584 stories on this site.